JNJ - Johnson & Johnson Stock Analysis
Johnson & Johnson (JNJ) is a publicly traded company listed on the NYSE. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 487.83B, generates annual revenue of 92.15B, and reports net income of 25.12B. As of the latest data, the stock is trading at 202.48 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. The stock offers a moderate dividend yield (2.56%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.78), indicating current market sentiment. Institutional ownership is reported at 74.47%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 30.80%, trading within a 52-week range of 140.68 - 207.81.
JNJ - Johnson & Johnson
202.48
Analyst Consensus
Hold 3.78
JNJ – Analyst Rating Summary
- Strong Buy: 6
- Buy: 13
- Hold: 13
- Sell: 0
- Strong Sell: 0
- Total Analysts: 32
| Index: | DJIA, S&P 500 | P/E: | 19.54 | EPS (ttm): | 10.36 | Insider Own: | 0.12% | Shs Outstand: | 2.41B | Perf Week: | -2.45% |
| Market Cap: | 487.83B | Forward P/E: | 17.58 | EPS next Y: | 11.52 | Insider Trans: | -7.63% | Shs Float: | 2.41B | Perf Month: | 8.36% |
| Income(ttm): | 25.12B | PEG: | 2.61 | EPS next Q: | 2.53 | Inst Own: | 74.47% | Short Float: | 0.84% | Perf Quarter: | 13.48% |
| Revenue(ttm): | 92.15B | P/S: | 5.29 | EPS this Y: | 8.87% | Inst Trans: | 0.30% | Short Ratio: | 2.30 | Perf Half Y: | 31.77% |
| Book/sh: | 32.95 | P/B: | 6.15 | EPS next Y: | 6.02% | ROA: | 13.54% | Short Interest: | 20.12M | Perf Year: | 30.80% |
| Cash/sh: | 7.70 | P/C: | 26.28 | EPS next 5Y: | 7.48% | ROE: | 33.62% | 52W Range: | 140.68 - 207.81 | Perf YTD: | 40.01% |
| Dividend Est.: | 5.19 (2.56%) | P/FCF: | 24.89 | EPS past 3/5Y: | -9.49% 0.55% | ROIC: | 21.16% | 52W High: | 207.81 -2.56% | Beta: | 0.33 |
| Dividend TTM: | 5.14 (2.54%) | Quick Ratio: | 0.80 | Sales past 3/5Y: | -1.79% 1.58% | Gross Margin: | 68.27% | 52W Low: | 140.68 43.93% | Perf 5Y: | 40.61% |
| Dividend Ex-Date: | Nov 25, 2025 | Current Ratio: | 1.07 | EPS Y/Y TTM: | 71.07% | Oper. Margin: | 25.79% | RSI (14): | 61.37 | Volatility: | 1.26% 1.49% |
| Employees: | 139800 | Debt/Eq: | 0.58 | Sales Y/Y TTM: | 5.08% | Profit Margin: | 27.26% | Recom: | 2.04 | Target Price: | 207.41 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.50 | EPS Q/Q: | 91.19% | Payout: | 84.80% | Rel Volume: | 1.02 | Prev Close: | 205.33 |
| Sales Surprise: | 1.00% | EPS Surprise: | 1.54% | Sales Q/Q: | 6.77% | Earnings: | Oct 14 BMO | Avg Volume: | 8.74M | Price: | 202.48 |
| SMA20: | 1.34% | SMA50: | 4.91% | SMA200: | 19.06% | Overbought: -2.43% | Volume: | 8,932,826 | Change: | -1.39% | |
Graham Classic formula value: 218.25
(P/E=8 * 1g) Min value: 144.01
(current P/E * 2g) Max value: 320.95
Average value: 227.74
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.